Recombinant roulette versus the apparent virtues of 'natural' cell receptor systems: Receptor genotypes versus phenotypes [1]

Trends in Pharmacological Sciences

Volumn 23, Issue 9, 2002, Pages 403-404

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; PHENYLETHANOLAMINE N METHYLTRANSFERASE INHIBITOR; RECOMBINANT RECEPTOR;

BETA ADRENERGIC RECEPTOR BLOCKING; CELL CULTURE; CELL MEMBRANE; DIMERIZATION; DRUG ACTIVITY; DRUG SCREENING; GENETIC ANALYSIS; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETIC TRANSFECTION; GENOTYPE; HORMONE RELEASE; HUMAN; KNOCKOUT MOUSE; LETTER; MOLECULAR CLONING; MOLECULAR RECOGNITION; PANCREAS CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION; STOICHIOMETRY;

DNA, COMPLEMENTARY; GENOTYPE; PHENOTYPE; RECEPTORS, DRUG; RECOMBINANT PROTEINS;

EID: 0036710360     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02046-1     Document Type: Letter

References (15)

1. McLatchie L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 393:1998;333-339.
2. Armour S.L., et al. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J. Pharmacol. Toxicol. Meth. 42:1999;217-224.
3. Chen W.J., et al. Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol. Pharmacol. 52:1997;1164-1175.
4. Christopoulous G., et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56:1999;235-242.
5. Devi L.A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 22:2001;532-537.
6. Traynor J., Elliot J. δ-Opioid receptor subtypes and cross talk with μ receptors. Trends Pharmacol. Sci. 14:1993;84-85.
7. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 399:1999;697-700.
8. 4-adrenoceptor' in mammalia heart. Clin. Exp. Pharmacol. Physiol. 24:1997;647-656.
9. 1-adrenergic receptor. Am. J. Physiol. Endocrinol. Metab. 43:2001;E199-E202.
10. 3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol. Pharmacol. 57:2000;252-258.
11. Rybin V.O. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae: a mechanism to functionally regulate the cAMP signaling pathway. J. Biol. Chem. 275:2000;41447-41457.
12. Hoel N.L., et al. Selective up-regulation of 5-HT(1B/1D) receptors during organ culture of cerebral arteries. NeuroReport. 12:2001;1605-1608.
13. Lelievre V., et al. Extrcellular adenosine deprivation induces epithelial differentiation of HT29 cells: evidence for a concomitant adenosine A(1)/A(2) receptor balance regulation. Eur. J. Pharmacol. 10:2000;21-29.
14. Makino I., et al. Phenotypic changes of adrenomedullin receptor components, RAMP2, and CRLR mRNA expression in cultured rat vascular smooth muscle cell. Biochem. Biophys. Res. Commun. 288:2001;515-520.
15. Corriu C., et al. ANG II receptor expression and function during phenotypic modulation of rat aortic smooth muscle cells. Am. J. Physiol. 266:1994;H631-H636.